Although 18 innovative antibiotics were approved by regulators in the wealthiest nations over the past decade, a new analysis finds few of these life-saving medicines were accessible due to delayed product launches stemming from concerns over sales and profitability.
Of those new antibiotics, most were available only in the U.S., the U.K., and Sweden, while only two were accessible in all 14 high-income countries that were examined. Just four antibiotics were launched in all of the 11 European countries where approvals and product launches were reviewed, according to the analysis published in Clinical Infectious Diseases.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
